Class Action Lawsuit Filed Against Aldeyra Therapeutics Over Alleged Securities Fraud
A class action lawsuit has been filed against Aldeyra Therapeutics (NASDAQ: ALDX) alleging securities fraud and unlawful business practices. The lawsuit follows the company's announcement of a Complete Response Letter from the FDA rejecting its New Drug Application for reproxalap, citing insufficient evidence of efficacy. The case has set a deadline for investors to seek appointment as Lead Plaintiff.
Topics: class action drug development FDA approval securities fraud stock price impact